<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272986</url>
  </required_header>
  <id_info>
    <org_study_id>OP512011</org_study_id>
    <nct_id>NCT01272986</nct_id>
  </id_info>
  <brief_title>Trial of Screening for ALOA-IgG AtheroAbzyme Test</brief_title>
  <acronym>OP512011</acronym>
  <official_title>Trial of Screening for ALOA-IgG AtheroAbzyme Test Comparing Healthy,Asymptomatic Myocardial Ischemic and Acute Coronary Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omicron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omicron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial of screening for ALOA-IgG AtheroAbzyme Test comparing healthy, asymptomatic
      myocardial ischemic and acute coronary syndrome patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring the degree of oxidized low-density lipoprotein (LDL) by ALOA- IgG AtheroAbzyme in healthy and cardiovascular disease patients</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Healthy patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic myocardial Ischemic patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Coronary Syndrome Patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ALOA IgG-Elisa</intervention_name>
    <description>measurement of IgG Level in blood</description>
    <arm_group_label>Healthy patients</arm_group_label>
    <arm_group_label>Asymptomatic myocardial Ischemic patients</arm_group_label>
    <arm_group_label>Acute Coronary Syndrome Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ALOA IgG-AtheroAbzyme</intervention_name>
    <description>measurement of IgG in blood</description>
    <arm_group_label>Healthy patients</arm_group_label>
    <arm_group_label>Asymptomatic myocardial Ischemic patients</arm_group_label>
    <arm_group_label>Acute Coronary Syndrome Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy patients

          -  High Risk patients or Asymptomatic myocardial Ischemic patients

          -  Acute Coronary Syndrome patients

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malek Mohamad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bahman Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bahman Hospital</name>
      <address>
        <city>Beirut</city>
        <state>Haret Hriek</state>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>March 6, 2011</last_update_submitted>
  <last_update_submitted_qc>March 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hisham Ramadan</name_title>
    <organization>Omicron Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Determination of the level of oxidised LDL by measuring the level of IgG in Blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

